Enzyme mimic nanomaterials as nanozymes with catalytic attributes.

Nanozymes are super-efficient nanomaterials with enzyme-like characteristics, as the name suggests. In the last decade, efforts have been made to develop "artificial enzymes," which are alternatives to natural enzymes. As nanoscience and nanotechnology advance, nanozymes, which are catalytic nanomaterials having enzyme-like properties, have fascinated researchers' attention. Nanozymes with unique physicochemical properties and nanomaterials that mimic catalytic activity have gained a special interest in the industrial sectors. However, several constraints have hampered their effective deployment in industrial processes, including denaturation, time-consuming manufacturing, overall high cost-ratio, and reutilization challenges. After a brief overview of nanozyme research, an analysis of the similarities and differences between nanozymes and natural and synthetic enzymes is presented. Because of their distinct properties, nanozymes stand out in this comparison. Nanozymes have exhibited a variety of applications leveraging the physiochemical properties of nanomaterials, ranging from in vitro detection to enzyme substitution in biological systems. In addition, nanozymes have introduced a new field called nanozymology, which blends nanotechnology with enzymology.

The hemochromatosis protein HFE inhibits iron export from macrophages.

Hereditary hemochromatosis (HH) is a disorder of iron metabolism caused by common mutations in the gene HFE. The HFE protein binds to transferrin receptor-1 (TfR1) in competition with transferrin, and in vitro, reduces cellular iron by reducing iron uptake. However, in vivo, HFE is strongly expressed by liver macrophages and intestinal crypt cells, which behave as though they are relatively iron-deficient in HH. These latter observations suggest, paradoxically, that expression of wild-type HFE may lead to iron accumulation in these specialized cell types. Here we show that wild-type HFE protein raises cellular iron by inhibiting iron efflux from the monocytemacrophage cell line THP-1, and extend these results to macrophages derived from healthy individuals and HH patients. In addition, we find that the HH-associated mutant H41D has lost the ability to inhibit iron release despite binding to TfR1 as well as wild-type HFE. Finally, we show that the ability of HFE to block iron release is not competitively inhibited by transferrin. We conclude that HFE has two mutually exclusive functions, binding to TfR1 in competition with Tf, or inhibition of iron release.

Dietary iron status has little effect on expression of ceruloplasmin but alters that of ferritin in rats.

Evidence supports a role for ceruloplasmin (ferroxidase I) in the release of iron to the blood from mammalian cells. However, recent studies with cultured cells have suggested that it has the opposite effect, and that iron deficiency enhances expression of ceruloplasmin. We therefore examined in rats how nutritional iron status would affect expression of ceruloplasmin. Groups of male Sprague-Dawley rats were reared on a low iron, starch-based diet for 6-8 wk; half were supplemented by injection of iron dextran. At killing, hematocrits of deficient rats were half normal. Supplemented rats had normal liver concentrations of ferritin and ferritin iron. No ferritin was detected in the livers of the deficient rats. Northern analysis showed that ferritin L and H mRNAs were present in the deficient livers, but expression was half that of the normal rats. There was also twice as much copper. Levels of circulating ceruloplasmin (measured by rocket immunoelectrophoresis) were not altered by iron deficiency, although p-phenylenediamine oxidase activity and plasma copper were reduced approximately 30%. In repeated studies, no differences in the expression of hepatic ceruloplasmin mRNA were detected. Treatment of rats of both sexes with additional iron (25 mg as iron dextran) 5-14 d before killing increased liver ferritin but did not alter liver ceruloplasmin mRNA expression or levels of circulating ceruloplasmin. We conclude that iron status is not an important factor in the expression of plasma ceruloplasmin made by the liver. However, it does have modest effects on steady-state levels of liver ferritin mRNA.